SCFAs could ameliorate the progression of hyperglycemia via a variety of mechanisms, including maintaining the integrity of the intestinal epithelial barrier (44), promoting liver glycogen metabolism (45), regulating the function of mitochondria (46), as well as promoting the release of Glucagon-like Peptide-1 (GLP-1) and peptide YY by activating GPR43 (47). The gene discussed is PYY; the disease is Hyperglycemia.